Deplante J P, Daumont A, Bouvier M, Lejeune E
Nouv Presse Med. 1978 Nov 25;7(41):3753-6.
An open trial of synthetic salmon thyrocalcitonin was carried out in 8 cases of progressive and multifocal Paget's disease over a period of three months and at a dose of 80 MRC.U twice daily. A clinical improvement was seen in half the cases. The action was also marked upon laboratory parameters with, in particular, an average decrease in alkaline phosphatase of 51% and in urinary hydroxyproline levels of 29.4%.
对8例进行性多灶性佩吉特病患者进行了合成鲑鱼降钙素的开放试验，为期三个月，剂量为每日两次，每次80 MRC单位。半数病例出现临床改善。对实验室参数也有显著作用，尤其是碱性磷酸酶平均下降51%，尿羟脯氨酸水平下降29.4%。
